These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26690748)

  • 41. A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets.
    Brzezniak C; Oronsky B; Aggarwal R
    Eur Urol; 2018 Feb; 73(2):306-307. PubMed ID: 28943185
    [No Abstract]   [Full Text] [Related]  

  • 42. Editorial Comment to Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.
    Sakamoto S
    Int J Urol; 2016 Aug; 23(8):653. PubMed ID: 27325306
    [No Abstract]   [Full Text] [Related]  

  • 43. Re: Positron Emission Tomography/Computed Tomography-based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-resistant Prostate Cancer.
    Rocco B; Eissa A; Bianchi G
    Eur Urol; 2018 Apr; 73(4):639-640. PubMed ID: 29274864
    [No Abstract]   [Full Text] [Related]  

  • 44. Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer?
    Di Nunno V; Santoni M; Massari F
    Lancet Oncol; 2018 Sep; 19(9):e437. PubMed ID: 30191844
    [No Abstract]   [Full Text] [Related]  

  • 45. Novel Androgen Receptor Signaling Inhibitors for Nonmetastatic Castration-Resistant Prostate Cancer: The Light at the End of the Tunnel-or an Oncoming Train?
    Harrison MR; Ramalingam S
    Oncology (Williston Park); 2016 Apr; 30(4):345-7. PubMed ID: 27085333
    [No Abstract]   [Full Text] [Related]  

  • 46. Treatment for castration-resistant prostate cancer and drug interaction risk in polymedicated patients.
    Juárez Soto A
    Actas Urol Esp (Engl Ed); 2020 Dec; 44(10):641-643. PubMed ID: 32829931
    [No Abstract]   [Full Text] [Related]  

  • 47. Re: Activation of Notch1 Synergizes with Multiple Pathways in Promoting Castration-Resistant Prostate Cancer.
    Atala A
    J Urol; 2017 Jun; 197(6):1458-1459. PubMed ID: 28505901
    [No Abstract]   [Full Text] [Related]  

  • 48. Re: Activation of Notch1 Synergizes with Multiple Pathways in Promoting Castration-Resistant Prostate Cancer.
    Atala A
    J Urol; 2017 Mar; 197(3 Pt 1):700-702. PubMed ID: 28208520
    [No Abstract]   [Full Text] [Related]  

  • 49. [The role of steroids in oncological practice].
    Küronya Z; Géczi L; Gyergyay F; Bíró K
    Orv Hetil; 2017 Oct; 158(42):1651-1657. PubMed ID: 29037061
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Re: Inhibition of the Hexosamine Biosynthetic Pathway Promotes Castration-Resistant Prostate Cancer.
    Atala A
    J Urol; 2017 Feb; 197(2):403. PubMed ID: 28093150
    [No Abstract]   [Full Text] [Related]  

  • 51. The success of therapies for metastatic CRPC continues.
    Shore ND
    Oncology (Williston Park); 2013 Nov; 27(11):1160-1. PubMed ID: 24575545
    [No Abstract]   [Full Text] [Related]  

  • 52. National Consensus on Non-metastatic Castration-Resistant Prostate Cancer: more than just a snapshot.
    Reis LO; Dal Col LSB; Sadi MV
    Int Braz J Urol; 2021; 47(2):374-377. PubMed ID: 33284539
    [No Abstract]   [Full Text] [Related]  

  • 53. Targeted α-Based Treatment of Metastatic Castration-Resistant Prostate Cancer: Revolutionizing Systemic Radiotherapy?
    Oyen WJ; de Bono JS
    J Nucl Med; 2016 Dec; 57(12):1838-1839. PubMed ID: 27539840
    [No Abstract]   [Full Text] [Related]  

  • 54. Reply to L. Dirix, B. De Laere et al, and A. Sharp et al.
    Armstrong AJ; Halabi S; Luo J; Nanus DM; Scher HI; Antonarakis ES; George DJ
    J Clin Oncol; 2019 Aug; 37(24):2184-2186. PubMed ID: 31265357
    [No Abstract]   [Full Text] [Related]  

  • 55. Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review.
    Anantharaman A; Friedlander TW
    Urol Oncol; 2016 Aug; 34(8):356-67. PubMed ID: 26706121
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data.
    Flaig TW; Potluri RC; Ng Y; Todd MB; Mehra M
    Cancer Med; 2016 Feb; 5(2):182-91. PubMed ID: 26710718
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.
    Shore ND; Chowdhury S; Villers A; Klotz L; Siemens DR; Phung D; van Os S; Hasabou N; Wang F; Bhattacharya S; Heidenreich A
    Lancet Oncol; 2016 Feb; 17(2):153-163. PubMed ID: 26774508
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostate Cancer, Version 1.2016.
    Mohler JL; Armstrong AJ; Bahnson RR; D'Amico AV; Davis BJ; Eastham JA; Enke CA; Farrington TA; Higano CS; Horwitz EM; Hurwitz M; Kane CJ; Kawachi MH; Kuettel M; Lee RJ; Meeks JJ; Penson DF; Plimack ER; Pow-Sang JM; Raben D; Richey S; Roach M; Rosenfeld S; Schaeffer E; Skolarus TA; Small EJ; Sonpavde G; Srinivas S; Strope SA; Tward J; Shead DA; Freedman-Cass DA
    J Natl Compr Canc Netw; 2016 Jan; 14(1):19-30. PubMed ID: 26733552
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality?
    Caffo O; Lunardi A; Trentin C; Maines F; Veccia A; Galligioni E
    Curr Drug Targets; 2016; 17(11):1301-8. PubMed ID: 26721408
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.
    Madan RA; Karzai FH; Ning YM; Adesunloye BA; Huang X; Harold N; Couvillon A; Chun G; Cordes L; Sissung T; Beedie SL; Dawson NA; Theoret MR; McLeod DG; Rosner I; Trepel JB; Lee MJ; Tomita Y; Lee S; Chen C; Steinberg SM; Arlen PM; Gulley JL; Figg WD; Dahut WL
    BJU Int; 2016 Oct; 118(4):590-7. PubMed ID: 26780387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.